A slate of deep-tech and health-tech startups disclosed new venture capital financing rounds, with backers including FCVC, Atlantic Blue Ventures, and Flat Capital.
Verified companies and investors
Pixelgen Technologies (Stockholm) confirmed a Series A financing round, backed by Atlantic Blue Ventures, through the company's official press announcements. Pixelgen develops next-generation spatial proteomics imaging technology. The round's financial terms — including size and post-money valuation — were not publicly disclosed.
Apollo Atomics and MaxQ Medical were also reported to have closed financing rounds. Apollo Atomics is advancing compact nuclear power technology; MaxQ Medical focuses on AI-driven cardiac monitoring platforms. Financial terms for both rounds were not disclosed by the companies or their investors.
What was not disclosed
Neither the companies nor their investors disclosed specific capital amounts, valuations, or detailed investor breakdowns beyond the names of the lead funding entities. The rounds were reported through a technology industry aggregator without formal press release documentation for each individual company.
Why it matters
The infusion of venture capital into niche deep-tech sectors — compact nuclear, cardiac AI monitoring, and spatial imaging — reflects continued investor interest in high-risk, high-potential scientific platforms. For each of these companies, the fresh capital is intended to accelerate product development, regulatory filings, and go-to-market activity.
Note: Financial figures and valuations for these rounds are not disclosed and cannot be verified. This report is limited to what has been confirmed through primary company announcements.
